Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Epithelial to mesenchymal transition and M2 macrophages drive aggressiveness in murine and human sarcomatoid urothelial carcinoma. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1016/j.eururo.2025.04.008
10.1016/j.eururo.2025.04.008 · External reference
Clinicopathologic and Survival After Cystectomy Outcomes in Squamous Cell Carcinoma of the Bladder
10.1016/j.clgc.2023.05.019 · 2023 · External reference
Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis
10.3233/blc-240008 · 2024 · External reference
10.1097/ju.0000000000000761
10.1097/ju.0000000000000761 · External reference
Pathological and oncological outcomes in patients with sarcomatoid differentiation undergoing cystectomy
10.1111/bju.15428 · 2022 · External reference
10.1007/s00345-016-1962-8
10.1007/s00345-016-1962-8 · External reference
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
10.1056/nejmoa2408154 · 2024 · External reference
Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer
10.1056/nejmoa2601486 · 2026 · External reference
10.1056/nejmoa2511674
10.1056/nejmoa2511674 · External reference
10.1056/nejmoa2312117
10.1056/nejmoa2312117 · External reference
Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study
10.1016/j.eururo.2025.09.003 · 2026 · External reference
10.3389/fonc.2022.930731
10.3389/fonc.2022.930731 · External reference
10.1038/s41698-023-00466-w
10.1038/s41698-023-00466-w · External reference
Progression-associated molecular changes in basal/squamous and sarcomatoid bladder carcinogenesis
10.1002/path.6060 · 2023 · External reference
Sarcomatoid areas of urothelial carcinoma are enriched for CD163-positive antigen-presenting cells
10.1002/2056-4538.70021 · 2025 · External reference
10.1093/nar/gkad1026
10.1093/nar/gkad1026 · External reference
10.1016/j.celrep.2019.04.048
10.1016/j.celrep.2019.04.048 · External reference
10.1016/j.eururo.2019.09.006
10.1016/j.eururo.2019.09.006 · External reference
10.1038/ng.3593
10.1038/ng.3593 · External reference
10.1016/j.cels.2015.12.004
10.1016/j.cels.2015.12.004 · External reference
10.1007/978-1-4939-7493-1_12
10.1007/978-1-4939-7493-1_12 · External reference
10.1158/1538-7445.am2018-3954
10.1158/1538-7445.am2018-3954 · External reference
10.1038/35074122
10.1038/35074122 · External reference
10.1371/journal.pone.0005623
10.1371/journal.pone.0005623 · External reference
10.1074/jbc.m112.408104
10.1074/jbc.m112.408104 · External reference
10.1158/0008-5472.can-09-2050
10.1158/0008-5472.can-09-2050 · External reference
Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials
10.1001/jamaoncol.2022.3707 · 2022 · External reference
10.1056/nejmoa1606774
10.1056/nejmoa1606774 · External reference
10.1056/nejmoa2034442
10.1056/nejmoa2034442 · External reference
Gender-specific Stratification of Survival Following Immune Checkpoint Inhibitor Therapy Based on Intratumoral Expression of a B cell Gene Signature. Eur
10.1016/j.euo.2021.07.003 · 2022 · External reference
10.1097/pas.0000000000002468
10.1097/pas.0000000000002468 · External reference
10.1056/nejmoa1613683
10.1056/nejmoa1613683 · External reference
10.1016/j.clgc.2024.102100
10.1016/j.clgc.2024.102100 · External reference
10.18632/oncotarget.10561
10.18632/oncotarget.10561 · External reference
Conditional ablation of TGF-β signaling inhibits tumor progression and invasion in an induced mouse bladder cancer model
2016 · External reference
10.1158/2159-8290.cd-23-1300
10.1158/2159-8290.cd-23-1300 · External reference
10.1016/j.heliyon.2024.e28332
10.1016/j.heliyon.2024.e28332 · External reference
10.1158/2159-8290.cd-25-1774
10.1158/2159-8290.cd-25-1774 · External reference
Towards circulating tumor DNA-guided treatment of muscle-invasive bladder cancer
10.21037/tau-24-7 · 2024 · External reference
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
10.1038/s41586-021-03642-9 · 2021 · External reference
Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma
10.1016/j.eururo.2023.06.007 · 2024 · External reference
10.1016/j.eururo.2025.11.011
10.1016/j.eururo.2025.11.011 · External reference
10.1097/ju.0000000000004828
10.1097/ju.0000000000004828 · External reference
10.3390/cells8101118
10.3390/cells8101118 · External reference
10.1073/pnas.1918167117
10.1073/pnas.1918167117 · External reference
Claudin-low bladder tumors are immune infiltrated and actively immune suppressed
10.1172/jci.insight.85902 · 2016 · External reference
10.1158/1535-7163.mct-10-0570
10.1158/1535-7163.mct-10-0570 · External reference
10.1038/ncomms6241
10.1038/ncomms6241 · External reference
10.1084/jem.20160801
10.1084/jem.20160801 · External reference
Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma
2015 · External reference
10.1186/s40425-019-0768-9
10.1186/s40425-019-0768-9 · External reference
10.1038/nature25501
10.1038/nature25501 · External reference
